Review of Non-Invasive Monitoring Systems, Inc. Motion Platform Device Published in Wolf Creek Conference on Cardiopulmonary Resuscitation.

NORTH BAY VILLAGE, Fla. -- Gary Macleod, Chief Executive Officer, Non-Invasive Monitoring Systems, Inc. (NIMS) (OTCBB:NIMU) announced that Dr. Jose A. Adams from Mt. Sinai Medical Center of Greater Miami published a review of "Endothelium and Cardiopulmonary Resuscitation" in the December issue of Critical Care Medicine. This paper was presented at the Eighth Wolf Creek Conference on Cardiopulmonary Resuscitation in June 2005 sponsored by the Institute of Critical Medicine in Rancho Mirage, CA.

Dr. Adams stressed that the release of beneficial substances from the inner lining of blood vessels, called the endothelium that is produced by a NIMS' patented motion platform technology during investigative cardiac arrest, is key to better cardiac and neurological outcomes in cardiac resuscitation of a large animal model. Dr. Adams added that mechanical stimulation of the endothelium by this non-invasive means has the advantage of not being limited to issues of bioavailability, distribution and toxicity as with drug stimulation of the endothelium.

Dr. Marvin Sackner, Chairman of the Board of Directors of NIMS stated that the device for human, non-CPR use is called the "Exer-Rest," which is a platform that repetitively moves a supine person lying on a mattress comfortably in a head to foot direction at about 140 times a minute with a displacement up to 3/4 inch over a period of 30 to 45 minutes. A clinical trial is planned to support the intended use of "Exer-Rest" for temporary relief of musculoskeletal pain associated with osteoarthritis of the hips in order to meet FDA approval for its marketing in the United States.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.